Scarica l'app Stockscreener
48.26
1.83%
-0.90
Dopo l'orario di chiusura:
48.19
-0.07
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$49.16
Aprire:
$48.5
Volume 24 ore:
12.43M
Relative Volume:
0.81
Capitalizzazione di mercato:
$163.61B
Reddito:
$46.69B
Utile/perdita netta:
$15.29B
Rapporto P/E:
14.06
EPS:
3.4329
Flusso di cassa netto:
$9.25B
1 W Prestazione:
+5.65%
1M Prestazione:
-14.83%
6M Prestazione:
-25.07%
1 anno Prestazione:
-54.18%
Intervallo 1D:
$48.03
$48.91
Intervallo di 1 settimana:
$45.57
$50.43
Portata 52W:
$45.05
$112.52
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.26 | 218.44B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,025.28 | 915.49B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
195.93 | 470.41B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
232.36 | 410.55B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.26 | 253.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
92.92 | 230.65B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Ripresa | Jefferies | Underperform |
| 2025-10-01 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-29 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Downgrade | UBS | Buy → Neutral |
| 2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Why Is Everyone Talking About Novo Nordisk Stock? - Finviz
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs - GlobeNewswire Inc.
Why Novo Nordisk Stock Is Sinking This Week - Finviz
Even With Pricing and Competitive Pressure, Novo Nordisk's Portfolio Warrants a Wide Moat - Morningstar
Novo Nordisk ADR earnings missed by $0.09, revenue fell short of estimates - Investing.com Australia
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts - Sahm
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx - Sahm
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes - Sahm
Can Novo Nordisk A s (b Shares) Adrhedged stock rebound after recent weaknessRecession Risk & Real-Time Volume Triggers - Fundação Cultural do Pará
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal - Sahm
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates - Investing.com South Africa
Will Novo Nordisk A s (b Shares) Adrhedged stock gain from strong economyExit Point & Trade Opportunity Analysis - fcp.pa.gov.br
Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs - Sahm
Wegovy maker Novo Nordisk cuts guidance again but Medicare pricing deal uplifts investors - The Globe and Mail
Novo Nordisk ADR earnings beat by $3.72, revenue topped estimates By Investing.com - Investing.com Nigeria
$NVO Last opportunity! for NYSE:NVO by alexei_erchov - TradingView
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It - Sahm
Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House - Sahm
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb - Sahm
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle - Sahm
Bengals-Bears game today: Chicago Bears outlast Cincinnati Bengals for wild 47-42 win on Williams' TD pass to Loveland - ABC7 Chicago
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' - Sahm
Will Novo Nordisk A s (b Shares) Adrhedged stock deliver strong dividend growthExit Point & Smart Investment Allocation Tips - fcp.pa.gov.br
Can Novo Nordisk A s (b Shares) Adrhedged stock outperform in 2025 bull marketJuly 2025 Chart Watch & Fast Momentum Entry Tips - fcp.pa.gov.br
P/E Ratio Insights for Novo Nordisk - Sahm
Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk - Sahm
Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail
Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):